This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
TheStreet) -- Lazard Capital Markets commenting on
"Now is the time to own Amarin shares over the balance of 2012, we believe."
Sounds bullish, as does Lazard's $26 price target, but take a closer look at the "valuation matrix" for Amarin offered by analyst Bill Tanner because it paints a less rosy picture.
Tanner concocts 10 possible commercial scenarios for Amarin's prescription fish-oil pill Vascepa. Four of them value Amarin shares between $4 and $11, meaning at or below the current stock price. The other six scenarios value Amarin shares between $13 and $39.
The average price of Tanner's Amarin "valuation matrix" works out to $17 per share -- a 50% bump from the stock's current level. Not bad, but a lower price target than the one espoused by die-hard Amarin bulls.
By the way, if you throw out the low and high scenarios in Tanner's calculations, Amarin's fair value falls to $15 per share, which is basically where the stock traded when Vascepa was approved in July. [And when <a href="http://www.thestreet.com/story/11645437/1/amarin-insiders-rush-to-sell-stock-one-day-after-fish-oil-pill-approval.html">Amarin insiders sold a large chunk of stock</a>.]
Sell-side analysts tend to be trailing indicators and that's certainly the case with Amarin. Investors have already figured out that Vascepa's future is clouded by uncertainty over the
long-delayed FDA decision on New Chemical Entity (NCE) status and the company's failure to spell out a clear commercialization plan. In this regard, analysts are telling investors stuff they already know.
Read through the most recent batch of Amarin sell-side notes and you'll notice a ratcheting down of expectations. Bullish takeout predictions are being discarded or significantly discounted. There's an admission now that the Vascepa NCE decision -- three or five years of market exclusivity -- is important where it was once regarded as trivial.
And perhaps most interesting, analysts are now talking more about the possibility that Amarin markets Vascepa on its own,
without a Big Pharma partner.
Jefferies analyst Thomas Wei, in a recent Amarin note:
"We believe it would be prudent for investors to assume that Amarin may very well announce that it plans to launch Vascepa on its own..."
[Wedbush <a href="http://www.thestreet.com/story/11726755/1/wall-street-losing-patience-with-amarin.html">downgraded Amarin</a> in early October for similar reasons.]
Amarin was supposed to provide details about Vascepa's commercial launch this month but that announcement has apparently been pushed back to November. Last year, Amarin announced third-quarter results on Nov. 7, so the company should have something to say fairly soon.
Amarin shares were down 1.5% to $11.09 in Monday trading.
-- Reported by Adam Feuerstein in Boston.Follow @AdamFeuerstein